Form 8-K - Current report:
SEC Accession No. 0001641172-25-009286
Filing Date
2025-05-08
Accepted
2025-05-08 16:35:12
Documents
15
Period of Report
2025-05-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 45227
2 EX-99.1 ex99-1.htm EX-99.1 41370
  Complete submission text file 0001641172-25-009286.txt   313598

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cing-20250508.xsd EX-101.SCH 3780
4 XBRL DEFINITION FILE cing-20250508_def.xml EX-101.DEF 26634
5 XBRL LABEL FILE cing-20250508_lab.xml EX-101.LAB 36717
6 XBRL PRESENTATION FILE cing-20250508_pre.xml EX-101.PRE 25258
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5714
Mailing Address 1901 W. 47TH PLACE KANSAS CITY KS 66205
Business Address 1901 W. 47TH PLACE KANSAS CITY KS 66205 (913) 942-2300
Cingulate Inc. (Filer) CIK: 0001862150 (see all company filings)

EIN.: 863825535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40874 | Film No.: 25926882
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)